Christopher A. Carter

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Yong S. Chang, Jalila Adnane, Pamela A. Trail et al. · Cancer Chemotherapy and Pharmacology · 2006 · 465 citations

Medicine, Oncology, Pharmacology +16

Requirement of essential fatty acid for mammary tumorigenesis in the rat.

Clement Ip, Christopher A. Carter, Margot M. Ip · PubMed · 1985 · 286 citations

Life Sciences, Nutrition, Nutritional Sciences +16

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006

Chunrong Yu, Laura M. Bruzek, Xue Meng et al. · Oncogene · 2005 · 274 citations

Life Sciences, Cell Biology, Oncology +15

Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat.

Christopher A. Carter, Richard J. Milholland, Wendy Shea et al. · PubMed · 1983 · 192 citations

Medicine, Oncology, Pharmacology +15